Directed share issue in OssDsign AB (SE) — SEK 150 million

Carnegie acted as sole bookrunner in the directed share issue of 26,315,790 new shares at a subscription price of SEK 5.7 per share. OssDsign is a developer and global provider of next generation bone replacement products. Based on cutting edge material science, the company develops and markets products that support the body’s own healing capabilities and thereby improve the clinical outcome in a wide range of orthopedic areas with high medical needs.